UNSPSC 51434701: Temocapril

This classification denotes an angiotensin-converting enzyme inhibitor and antihypertensive agent with the molecular formula C23H28N2O5S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 18IZ008EU6, chemically known as 1,4-thiazepine-4(5h)-acetic acid, 6-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)tetrahydro-5-oxo-2-(2-thienyl)-, (2s-(2alpha,6beta(r*)))- but generally known as temocapril, which bears US NIH Compound Identifier 71323.

UNSPSC 51434701 Temocapril, a Commodity code, represents pharmaceutical products that state and local governments procure for emergency medical services, health agency benefit programs, and institutional healthcare operations. Recent solicitations show state and local buyers acquiring emergency medications, generic pharmaceuticals, and over-the-counter products through competitive sealed-bid and cooperative purchasing arrangements. The City of Tampa's fire rescue department, the Texas Health and Human Services Commission, and multistate cooperative purchasing alliances all active in this space source medications and pharmaceutical products through formal procurement channels, indicating a mix of municipal emergency services departments, state health agencies, and cooperative purchasing vehicles managing pharmaceutical supply chains for public health operations.

Activity appears concentrated in Texas, Florida, and the upper Midwest, with multistate cooperative purchasing extending reach across multiple jurisdictions including Oregon. The City of Tampa's Purchasing Department issued an IFB (Bid No. 26-P-00188) on April 24, 2026, for Advanced Life Support Medications including Labetalol HCI, Epinephrine, Adenosine, and Diltiazem vials for Tampa Fire Rescue, with a response deadline of April 8, 2026 and an estimated contract value of $40,000.00; the city applied a 5 percent bid discount for Small Local Business Enterprise participation capped at $10,000. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP on January 20, 2026, due March 26, 2026, for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities through three authorized wholesalers, with evaluation weighted 75 percent on price competitiveness. The Texas Health and Human Services Commission issued an RFI on April 3, 2026, seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling exploratory procurement activity in pharmaceutical benefit program restructuring. Bidders on medication solicitations must typically provide Safety Data Sheets, cGMP and DSCSA certifications, firm pricing including shipping and applicable taxes, and warranties covering expiration-date thresholds and material defects.